13 RESULTS
COMMENT Dr. Braudeau is correct that the performance of blood biomarkers may vary in cognitively impaired and cognitively unimpaired groups. However, this paper only considers use of blood biomarkers in determining the presence/absence of amyloid pathology in pat
COMMENT Although no blood tests for Alzheimer’s disease pathology have yet been approved by the FDA, an increasing number of minimally regulated laboratory-developed tests (LDTs) are clinically available. There is very wide variation in the accuracy and validatio
COMMENT Kac and colleagues validated an immunoassay for plasma p-Tau212 in multiple clinical and autopsy cohorts. They demonstrated that their p-Tau212 antibody does not cross-react with p-Tau217. However, the results for their plasma p-Tau212 and p-Tau217 assays
COMMENT Karikari and colleagues demonstrated that brain-derived tau, measured in plasma, performed similarly to CSF in distinguishing AD-biomarker-positive individuals. They performed an impressive number of studies in five different cohorts to validate their ass
COMMENT Karikari and colleagues demonstrated that brain-derived tau measured in plasma performed similarly to CSF BD-tau in distinguishing AD-biomarker-positive individuals. They performed an impressive number of studies in five different cohorts to validate thei
COMMENT Milá-Alomá et al. evaluated plasma biomarkers in the ALFA+ cohort to see which captured early changes in amyloid accumulation. They report that plasma p-tau231 reached abnormal levels with the lowest amyloid burden. However, a key caveat to consider is th
COMMENT Studies have demonstrated that diagnosis of symptomatic Alzheimer's disease based on clinical criteria alone leads to a significant rate of misdiagnosis. In one large study, 25 percent of patients diagnosed with symptomatic AD were amyloid-PET-negati
COMMENT Outside of Aβ42 and Aβ40, few species of Aβ are typically studied. Liu and colleagues performed a variety of experiments to characterize less-commonly-described forms of Aβ: They examined Aβ profiles produced by cell lines expressing familial AD mutations
COMMENT This paper shows an analysis of longitudinal tau PET with the 18F-RO948 tracer, which may have less off-target binding than flortaucipir. These data show clear progression of tau PET pathology that is largely consistent with neuropathologically establishe
COMMENT Algorithms that predict progression to AD dementia using blood-based measures and readily available individual-level factors (e.g., age and APOE genotype) are likely to be very useful in research, clinical trials, and the clinic. Adding cognitive test sco
COMMENT The data on blood tests for AD, both Aβ42/Aβ40 and pTau isoforms, are quite exciting to me as both a researcher and a clinician. Algorithms that incorporate individual-level factors (e.g., age, sex, APOE genotype, race) and multiple biomarkers are likely
COMMENT This paper provides further evidence that plasma ptau181 may be an excellent blood-based biomarker for Alzheimer disease brain pathology and symptomatic status. Interestingly, the investigators found very high intra-individual variation in p-tau181 levels
COMMENT Shahim et al. studied a fairly small sample (16 hockey players and 15 controls). There was no difference between CSF NfL levels in study participants with postconcussion syndrome versus controls. However, there was a slightly significant (p=0.04) differen
